Derivatives of human complement component C3 for therapeutic complement depletion: A novel class of therapeutic agents

David C. Fritzinger, Brian E. Hew, June Q. Lee, James Newhouse, Maqsudul Alam, John R. Ciallella, Mallory Bowers, William B. Gorsuch, Benjamin J. Guikema, Gregory L. Stahl, Carl Wilhelm Vogel

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

13 Scopus citations

Abstract

To obtain proteins with the complement-depleting activity of Cobra Venom Factor (CVF), but with less immunogenicity, we have prepared human C3/CVF hybrid proteins, in which the C-terminus of the α-chain of human C3 is exchanged with homologous regions of the C-terminus of the β -chain of CVF. We show that these hybrid proteins are able to deplete complement, both in vitro and in vivo. One hybrid protein, HC3-1496, is shown to be effective in reducing complement-mediated damage in two disease models in mice, collagen-induced arthritis and myocardial ischemia/reperfusion injury. Human C3/CVF hybrid proteins represent a novel class of biologicals as potential therapeutic agents in many diseases where complement is involved in the pathogenesis.

Original languageEnglish
Title of host publicationCurrent Topics in Complement II
PublisherSpringer New York
Pages293-307
Number of pages15
ISBN (Print)9780387789514
DOIs
StatePublished - 2008
Externally publishedYes

Publication series

NameAdvances in Experimental Medicine and Biology
Volume632
ISSN (Print)0065-2598

Fingerprint

Dive into the research topics of 'Derivatives of human complement component C3 for therapeutic complement depletion: A novel class of therapeutic agents'. Together they form a unique fingerprint.

Cite this